Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases, including obesity and diabetes,and has gradually become the most common cause of chronic liver disease. We investigated the effects of sodium glucose cotrans porter 2 (SGLT2) inhibitor canagliflozin on NAFLD in high-fat diet (HFD)-induced obese mice and possible underlying mecha nisms. Materials and Methods: Male C57BL/6 mice were fed a normal-diet, HFD, or HFD with canagliflozin for 14 weeks. AML-12 hepa tocytes were treated with canagliflozin. Expression of related pathways was assessed. Results: Canagliflozin administration reduced body weight and fat mass, compared with HFD alone. Canagliflozin improved glu cose and lipid metabolic disorders. Compared with HFD-fed mice, liver weight, serum alanine transaminase (ALT) levels, and he patic lipid accumulation were decreased after canagliflozin administration. Additionally, canagliflozin upregulated lipolysis mark ers (CPT1a, ACOX1, and ACADM), downregulated lipogenesis markers (SREBP-1c and FASN), and suppressed the production ofinflammatory cytokines (TNFα, MCP1, IL-1β, and IL-6), consistent with significantly increased LC3 II/I and Atg7 levels in the liverfollowing canagliflozin treatment. In vitro, canagliflozin increased CPT1a, ACOX1, and ACADM expression, decreased SREBP-1cand FASN protein expression, and reduced TNFα, MCP1, IL-1β, and IL-6 mRNA levels in lipid mixture (LM)-induced hepatocytesin a dose-dependent manner. These changes were reversed by 3-MA, an autophagy inhibitor. Conclusion: Our findings suggest that canagliflozin ameliorates the pathogenesis of NAFLD by regulating lipid metabolism andinhibiting inflammation, which may be associated with its promotion of autophagy.
Abstract
Purpose: Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases, including obesity and diabetes,and has gradually become the most common cause of chronic liver disease. We investigated the effects of sodium glucose cotrans porter 2 (SGLT2) inhibitor canagliflozin on NAFLD in high-fat diet (HFD)-induced obese mice and possible underlying mecha nisms. Materials and Methods: Male C57BL/6 mice were fed a normal-diet, HFD, or HFD with canagliflozin for 14 weeks. AML-12 hepa tocytes were treated with canagliflozin. Expression of related pathways was assessed. Results: Canagliflozin administration reduced body weight and fat mass, compared with HFD alone. Canagliflozin improved glu cose and lipid metabolic disorders. Compared with HFD-fed mice, liver weight, serum alanine transaminase (ALT) levels, and he patic lipid accumulation were decreased after canagliflozin administration. Additionally, canagliflozin upregulated lipolysis mark ers (CPT1a, ACOX1, and ACADM), downregulated lipogenesis markers (SREBP-1c and FASN), and suppressed the production ofinflammatory cytokines (TNFα, MCP1, IL-1β, and IL-6), consistent with significantly increased LC3 II/I and Atg7 levels in the liverfollowing canagliflozin treatment. In vitro, canagliflozin increased CPT1a, ACOX1, and ACADM expression, decreased SREBP-1cand FASN protein expression, and reduced TNFα, MCP1, IL-1β, and IL-6 mRNA levels in lipid mixture (LM)-induced hepatocytesin a dose-dependent manner. These changes were reversed by 3-MA, an autophagy inhibitor. Conclusion: Our findings suggest that canagliflozin ameliorates the pathogenesis of NAFLD by regulating lipid metabolism andinhibiting inflammation, which may be associated with its promotion of autophagy.
참고문헌 (40)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Goldberg D, "Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation", Gastroenterology, 152, pp.1090~1099.e1 (2017)
- Mittal S, "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131.e1 (2016)
- Drew L, "Fighting the fatty liver", Nature, 550, pp.S102~S103 (2017)
- Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
- Samuel VT, "Nonalcoholic fatty liver disease, insulin resistance, and ceramides", N Engl J Med, 381, pp.1866~1869 (2019)
- Mantovani A, "Nonalcoholic fatty liver disease and risk of incident type 2 diabetes : a meta-analysis", Diabetes Care, 41, pp.372~382 (2018)
- Bril F, "Management of nonalcoholic fatty liver disease in patients with type 2 diabetes : a call to action", Diabetes Care, 40, pp.419~430 (2017)
- Birkeland KI, "Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs(CVD-REAL Nordic) : a multinational observational analysis", Lancet Diabetes Endocrinol, 5, pp.709~717 (2017)
- Mahaffey KW, "Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups : results from the randomized CREDENCE trial", Circulation, 140, pp.739~750 (2019)
- Preiss D, "Research digest : SGLT2 inhibition in kidney and liver disease", Lancet Diabetes Endocrinol, 7, pp.427~ (2019)
- Kabil SL, "Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2glycoprotein up-regulation", Eur J Pharmacol, 828, pp.135~145 (2018)
- Jojima T, "The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis : association with SGLT2 expression in hepatocellular carcinoma", Int J Mol Sci, 20, pp.5237~ (2019)
- Inoue M, "Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease", J Diabetes Investig, 10, pp.1004~1011 (2019)
- Wei D, "Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro", Can J Physiol Pharmacol, 99, pp.775~785 (2021)
- Wei D, "Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro", Life Sci, 247, pp.117414~ (2020)
- Xu Z, "Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6", STAT3 axis in renal cell carcinoma, 2017, pp.36, 1965~1977
- Liu Z, "A NIK-SIX signalling axis controls inflammation by targeted silencing of non-canonical NF-κB", Nature, 568, pp.249~253 (2019)
- Byrne CD, "What’s new in NAFLD pathogenesis, biomarkers and treatment?", Nat Rev Gastroenterol Hepatol, 17, pp.70~71 (2020)
- Liang Y, "Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models", PLoS One, 7, pp.e30555~ (2012)
- Ji W, "Effects of canagliflozin on weight loss in high-fat diet-induced obese mice", PLoS One, 12, pp.e0179960~ (2017)
- Naznin F, "Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice", Eur J Pharmacol, 794, pp.37~44 (2017)
- Tasneem AA, "Factors predicting non-alcoholic steatohepatitis(NASH)and advanced fibrosis in patients with non-alcoholic fatty liver disease(NAFLD)", Trop Doct, 48, pp.107~112 (2018)
- Wang YN, "CPT1Amediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis", Oncogene, 37, pp.6025~6040 (2018)
- Griffin EN, "Lipid metabolism and axon degeneration : an ACOX1 balancing act", Neuron, 106, pp.551~553 (2020)
- Bruun GH, "A synonymous polymorphic variation in ACADM exon 11 affects splicing efficiency and may affect fatty acid oxidation", Mol Genet Metab, 110, pp.122~128 (2013)
- Zhang Y, "Xyloketal B Attenuates fatty acid-induced lipid accumulation via the SREBP-1c pathway in NAFLD models", Mar Drugs, 15, pp.163~ (2017)
- Shimano H, "SREBP-regulated lipid metabolism : convergent physiology-divergent pathophysiology", Nat Rev Endocrinol, 13, pp.710~730 (2017)
- Pafili K, "Nonalcoholic fatty liver disease(NAFLD)from pathogenesis to treatment concepts in humans", Mol Metab, 50, pp.101122~ (2021)
- Kang A, "SGLT2 inhibitors may offer benefit beyond diabetes", Nat Rev Nephrol, 17, pp.83~84 (2021)
- Zhang Y, "Targeting autophagy in obesity : from pathophysiology to management", Nat Rev Endocrinol, 14, pp.356~376 (2018)
- Lim H, "A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes", Nat Commun, 9, pp.1438~ (2018)
- Martinez-Lopez N, "Autophagy and lipid droplets in the liver", Annu Rev Nutr, 35, pp.215~237 (2015)
- Madrigal-Matute J, "Regulation of liver metabolism by autophagy", Gastroenterology, 150, pp.328~339 (2016)
- Tanaka S, "Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice", Hepatology, 64, pp.1994~2014 (2016)
- Hsiao PJ, "Pioglitazone enhances cytosolic lipolysis, β-oxidation and autophagy to ameliorate hepatic steatosis", Sci Rep, 7, pp.9030~ (2017)
- Sun Y, "Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21", Br J Pharmacol, 175, pp.374~387 (2018)
- Huang R, "Deacetylation of nuclear LC3 drives autophagy initiation under starvation", Mol Cell, 57, pp.456~466 (2015)
- Frudd K, "Oxidation of Atg3 and Atg7 mediates inhibition of autophagy", Nat Commun, 9, pp.95~ (2018)
- Jin K, "PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis", Theranostics, 10, pp.5290~5304 (2020)